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Nineteen patients infected with human immunodeficiency virus (HIV) with varying levels
of viral suppression achieved with antiretroviral therapy were evaluated to determine whether
trivalent influenza vaccine activated HIV replication. Humoral immune responses and CD4+
lymphocyte subsets were compared in 5 HIV-uninfected vaccinated subjects. Transient ele-
vations of plasma HIV RNA levels (76–89 copies/mL) appeared within 2 weeks in 3 of 11
patients with !50 copies/mL at baseline. Sustained elevation in HIV plasma RNA was observed
in 7 of 8 patients with baseline HIV RNA of 150 copies/mL. HIV DNA decreased in patients
with !400 RNA copies/mL at baseline and showed an HIV RNA increase after vaccination
( ) when compared with 8 patients with !50 copies/mL at baseline who lacked viral re-n = 8
sponse to vaccination. Concurrent decreases in proviral DNA and memory phenotype CD4+
cells in association with increased plasma HIV RNA after vaccination in patients with !400
RNA copies/mL at baseline suggest that in vivo mobilization of the latently infected cell
reservoir may occur during potent antiretroviral therapy.
A reservoir of latently infected CD4CD45RO1 T cells har-
boring replication-competent virus persists in human immu-
nodeficiency virus (HIV)–infected patients who have achieved
high-level viral suppression with potent antiretroviral therapy
[1–3]. These latently infected memory cells turn over very slowly
[4, 5], implying protracted decay of this virus pool. Activation
of the latent cell reservoir in vitro upon T cell stimulation by
various methods suggests that such activation of these cells
might also occur in vivo and provides a rationale for evaluating
therapeutic interventions that activate these cells and poten-
Received 6 July 1999; revised 28 October 1999; electronically published
8 February 2000.
Presented in part: 12th World AIDS Conference, Geneva, 28 June–3 July
1998 (abstract 21113); 6th Conference on Retroviruses and Opportunistic
Infections, Chicago, 31 January–4 February, 1999 (abstract 337).
Informed consent was obtained from all patients who participated in this
study, and human experimentation guidelines of the US Department of
Health and Human Services and those of the University of California San
Diego were followed in the conduct of clinical research.
Grant support: Swiss National Science Foundation (84AD-046176,
H.F.G.); VA Career Development Award (J.K.W.); VA Merit Award
(C.A.S.); NIH (AI 43752, J.K.W.; AI 27670, AI 38858, AI 36214, Center
for AIDS Research; AI 29164); Research Center for AIDS and HIV Infec-
tion of the San Diego Veterans Affairs Medical Center.
Reprints or correspondence: Dr. Huldrych Gu¨nthard, University Hospital
of Zurich, Dept. of Medicine, Division of Infectious Diseases and Hospital
Epidemiology, Ra¨mistrasse 100, CH-8091 Zu¨rich, Switzerland (huldrych
.guenthard@dim.usz.ch).
The Journal of Infectious Diseases 2000;181:522–31
q 2000 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2000/18102-0016$02.00
tially accelerate clearance of virus. The influenza virus and tet-
anus toxoid vaccines, both of which are T cell–dependent com-
mon recall antigens, have been shown to induce T cell activation
and type 1 cytokine production [6], enhance HIV isolation from
peripheral blood mononuclear cells (PBMC) of HIV-infected
patients, increase viral burden in lymphoid tissue, and induce
transient increases in HIV-1 viral load after immunization
[7–11]. In addition, the in vitro infectability of PBMC from
HIV-uninfected subjects is augmented after immunization with
tetanus toxoid vaccine [11]. PBMC from such uninfected in-
dividuals show a higher proportion of CD45RO1 CD4 memory
cells and a decrease of CD45RA1 naive CD4 cells after 6 days
of ex vivo stimulation with influenza antigens [12].
The increase of HIV RNA levels after influenza vaccination
can be explained by several mechanisms. Vaccination may in-
duce expansion of permissive target cells and activate latently
infected quiescent CD45RO1 memory CD4 cells. Alternatively,
it could upregulate chronically infected, virus-producing cells
nonspecifically through the release of activating cytokines. To
obtain insight into the relative contributions of these mecha-
nisms, we studied the effects of influenza vaccination in HIV-
infected patients who had either undetectable plasma RNA
levels, low-level plasma viremia (50–400 RNA copies at base-
line), or HIV RNA levels 1400 copies/mL.
Patients and Methods
Patients. Patients were prospectively enrolled in the study dur-
ing September 1997 at the San Diego Veterans Affairs Health Care
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Table 1. Baseline characteristics of study subjects.
Level of plasma RNA suppression at baseline
!50
copies/mL
50–400
copies/mL
1400
copies/mL
Total HIV-
infected patients
HIV-uninfected
control subjects
No of patients 11 5 5 21 5
Proviral DNA, copies/mg genomic DNA 145 (16–587) 216 (15–759) 197 (84–1414) 173 (15–1414) —
CD41 cells
Absolute CD41 cells/mm3 389 (104–761) 461 (219–709) 373 (118–594) 404 (104–761)a 882 (759–1268)a
% total CD41 count 21 (6–37) 19 (10–28) 23 (12–32) 21 (6–37)a 44 (34–56)a
% CD45RA1CD62L1 (of CD4 naive cells) 27 (7–62) 37 (17–64) 32 (17–40) 30 (7–64) 43 (20–59)
% CD45RO1CD251 (of CD4 memory cells) 36 (10–49) 28 (13–31) 31 (28–34) 33 (10–49) 38 (26–52)
NOTE. Data are mean (range). HIV, human immunodeficiency virus.
a Healthy controls and all HIV-infected patients ( ) are significantly different ( ).n = 19 P ! .05
System (VA) according to institutional review board guidelines. All
subjects had consented to receive the annual influenza vaccine. For
HIV-infected subjects, entry criteria included age 118 years, treat-
ment with triple- or double-drug antiretroviral therapy, HIV
plasma RNA !400 RNA copies/mL for at least 3 months before
vaccination, and no opportunistic infection within the previous 3
months. HIV-negative controls were 118 years of age and without
serious acute or chronic illness. Blood was collected at baseline
(immediately before vaccination with trivalent influenza vaccine
[season 1997/98; Wyeth-Ayerst Research Laboratories, St. Davis,
PA]) and at weeks 1, 2, 4, and 6–8. Drug interruptions and interim
infections were noted. At all study visits, HIV RNA was quanti-
tated from plasma with the Amplicor Monitor assay (Roche Mo-
lecular Systems, Somerville, NJ) [13]. The Roche ultrasensitive as-
say, with a limit of detection of 50 copies/mL, was performed on
plasma samples with values !400 copies/mL. Although patients
were required to have a recent viral load of !400 copies/mL, HIV
plasma RNA was 1400 copies/mL in 3 subjects at baseline. Patients
were segregated into 3 groups according to their baseline RNA
levels: group 1, “suppressed,” (baseline RNA level !50 copies/mL);
group 2: “partially suppressed” (baseline RNA level: 50–400 copies/
mL); and group 3: “unsuppressed” 1400 copies/mL at baseline.
Five HIV-uninfected volunteers were enrolled as controls.
PBMC-associated proviral HIV DNA. Proviral DNA levels
were quantitated by use of a prototype assay developed at Roche
Molecular Systems, Alameda, CA [14]. PBMC pellets were thawed
and washed once with 1 mL of Specimen Wash Solution (Roche
Molecular Systems). The cells were pelleted by centrifugation at
16,000 g for 3 min and lysed with a buffer that contains proteinase
K and an internal quantitation standard (QS). The QS is a plasmid
DNA that has the same primer binding sites as the target but
contains a different probe region, similar to that described by
Mulder et al. [13]. After heat inactivation of the proteinase K, the
samples were amplified by use of the Amplicor Monitor v1.5 HIV-
1 master mix (Roche Molecular Systems). Detection was performed
by use of microwell plates coated with HIV and QS specific probes
[13]. Total DNA was determined with Hoechst dye as recom-
mended by the manufacturer (Amersham Pharmacia Biotech, Pis-
cataway, NJ). The final DNA concentration was multiplied by 2
to correct for the 2-fold reduction in the binding of Hoechst dye
to single-stranded DNA. The final number reported is HIV-1 DNA
copies/mg of total DNA.
Hemagglutination inhibition assay. Serum antibodies to influ-
enza antigens were measured in a standard hemagglutinin inhibi-
tion assay [15]. To remove nonspecific inhibitors, serum was treated
with receptor-destroying enzyme (RDE; Bio Whittaker, Walkers-
ville, MD). Twofold serum dilutions starting at 1 : 10 were tested
against monovalent antigens B/HARBIN/07/94, A/JOHANNES-
BURG/82/96, and A/NANCHANG/933/95 (4 HA units/0.025 mL
antigen [Centers for Disease Control, WHO Influenza Center, At-
lanta, GA]).
T cell subset phenotyping. T cell subsets were assessed in whole
blood specimens within 4 h of collection into EDTA anticoagulant.
Multicolor fluorescence-activated cell sorter (FACS) analysis was
performed on a FACScan instrument (Becton Dickinson Cyto-
metry Systems, San Jose, CA) with use of a CD4 (bright) anchor
gate (CyChrome-conjugated antibodies) in conjunction with pre-
titrated, premixed fluorescein isothiocyanate (FTIC)/phosphati-
dylethanolamine (PE)–conjugated monoclonal antibody combi-
nations that included CD45RA/CD62L, CD45RO/CD25, (Phar-
Mingen, San Diego, CA).
Statistics. Correlations were calculated by the least-squares
method. Statistical analyses were performed by use of SPSS version
6.1 (SPSS, Irvine CA). Analysis of variance, 2-tailed t-test, Wil-
coxon rank sum test, and x2 test were used
Results
Patient characteristics. Eleven subjects had baseline RNA
!50 copies/mL (group 1), 5 had 50–400 RNA copies/mL (group
2), and 3 had 1400 copies/mL (group 3). Group 1 and group
2 patients all received triple combination therapy containing a
protease inhibitor (indinavir, ; nelfinavir, ) and eithern = 15 n = 1
AZT/3TC ( ), d4T/3TC ( ), efavirenz/3TC ( ), orn = 9 n = 5 n = 1
nevirapine/d4T ( ). In group 3, 1 patient was taking rito-n = 1
navir/saquinavir, 1 was taking AZT/3TC, and 1 had all anti-
retroviral therapy stopped because of drug toxicities 4 weeks
before vaccination. The mean baseline CD41 cell counts for
the entire patient cohort was 404 cells/mm3; baselines were sim-
ilar among the 3 groups (table 1). The mean duration of un-
detectable plasma HIV RNA levels (!400 RNA copies/mL) was
8 months (range, 3–14 months) for group 1 and 7 months
(range, 3–9 months) for group 2. The average age of HIV-
infected patients and healthy controls was 43 (range, 28–63
years) and 42 years (range, 35–54 years), respectively, and was
similar among groups 1,2, and 3. These baseline characteristics
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Figure 1. Logarithmic scale of plasma RNA at baseline and peak
viremia at weeks 1 and 2 from 19 patients infected with human im-
munodeficiency virus. Horizontal, thick broken line represents sensi-
tivity of the assay when limit of detection was set at 50 copies/mL.
Group 1: dotted lines, ; group 2: solid lines, ; group 3:n = 11 n = 5
dashed lines, .n = 3
were not statistically significant between groups. All but 2 of
the HIV-infected subjects and all but 1 of the HIV-uninfected
subjects had received influenza vaccination within the last 2
years before study initiation. Therapy was not changed during
the study period except for 2 patients from group 3 at week 4
because of poor control of viremia. Two patients with 1400
RNA copies/mL at baseline were not included into group 3 for
RNA, DNA, and lymphocyte subset analysis because of non-
adherence but were included in the analysis of humoral immune
response to influenza vaccination. In 1 patient of group 1, tho-
racic herpes zoster was newly diagnosed on the third study
week. No further infections or other diseases were observed.
HIV-1 plasma RNA. In group 1 (baseline RNA levels !50
copies/mL), 3 patients showed detectable RNA levels of 76
( ) and 89 copies/mL ( ) at week 1 and at week 2 aftern = 1 n = 2
vaccination, respectively (figure 1). HIV plasma RNA from
those 3 patients was only transient and not detected again dur-
ing the 8-week study period or the subsequent 8 months of
follow up. The remaining 8 patients from group 1 had unde-
tectable plasma RNA levels for the entire study period, with
the exception of 1 subject who failed therapy at week 8 because
of admitted nonadherence (5349 HIV RNA copies/mL; figure
2).
In group 2, 4 of 5 patients experienced a plasma RNA in-
crease within the first 2 weeks after vaccination (3 with >0.5
log, 1 with 0.25 log); the fifth patient had an increase of 0.9
log at week 4 (figure 1). RNA increases were sustained at week
8 in 4 of the 5 patients (3 with >0.5 log, 1 with 0.3 log; figure
2). At week 8, treatment regimens in these individuals were
changed, rendering subsequent data unsuitable for analysis.
All 3 patients from group 3 showed RNA increases that
peaked at week 1 after influenza vaccination (1 with 1 log10,
and 2 with 0.4 log10). At week 2, plasma viremia declined in
all 3 patients. However, by week 4, plasma viremia increased
above baseline in 2 of the 3 patients (0.5–0.7 log10; figure 2).
Therapy was changed in 1 patient, and the subject with the
highest HIV RNA increase (10-fold) restarted a new “salvage”
regimen after having been off treatment for 8 weeks. Therapy
of the third patient in group 3 was changed at week 8.
Vaccine-induced elevation in HIV RNA was correlated with
baseline RNA levels. None of the 11 patients from group 1,
but 4 of 8 patients in groups 2 and 3 showed a 0.5 log10 increase
in HIV RNA at weeks 1 or 2 ( ). Seven of 8 patientsP = .004
from groups 2 and 3 and only 3 of 11 patients in group 1 showed
any detectable increase in HIV RNA ( ). There was aP = .007
linear relationship between baseline HIV RNA and HIV RNA
at weeks 1 or 2 ( ) that was independent of baselineP = .002
CD41 count ( ).P = .5
Proviral DNA. At baseline, patients in group 1 (!50 RNA
copies/mL) had the lowest proviral DNA level, with a mean of
145 copies/mg genomic DNA (range, 16–587 copies/mg). The
means of groups 2 and 3 were higher: 216 (range, 15–759 copies/
mg) and 197 (range, 84–1414 copies/mg) HIV DNA copies/mg,
respectively. When patients were stratified based on their pat-
tern of HIV plasma RNA response to vaccination, no change
in proviral DNA levels was observed in the 8 patients who had
no measurable plasma viremia over the 8-week study period
(figure 3A). The 3 patients who had a low but measurable HIV
RNA increase at weeks 1 or 2 after vaccination showed a slight
decrease of PBMC-associated proviral DNA at weeks 2 and 4
that returned to baseline levels by week 8. A similar pattern of
HIV response was found in patients with a baseline plasma
viremia of 50–400 copies/mL. These 8 patients showed a mean
decrease from baseline of 257 DNA copies/mg genomic DNA
(range, 2185 to 186 copies/mg) at week 2 and a further re-
duction to 283 DNA copies/mg genomic DNA (range, 2289
to 170 copies/mg) from baseline at week 4 (figure 3B). However,
the observed decline in HIV DNA did not reach significance
at either week 2 ( ) or week 4 ( ), when comparedP = .15 P = .1
with patients from group 1 (figure 3A). Subjects with baseline
plasma viremia 1400 copies/mL displayed the opposite pattern
of response, with a mean proviral DNA increase of 84 copies/
mg genomic DNA (range, 21 to 1248 copies/mg) at week 2,
increasing to 317 copies/mg genomic DNA at week 4 (range,
218.5 to 1977 copies/mg; figure 3C). When the mean change
of proviral DNA in this third patient group was compared with
that of 8 patients with !400 RNA copies at baseline and an
RNA response upon vaccination (figure 3B), borderline sig-
nificance between the groups was reached for weeks 2 and 4
( ); however, no significant difference was seen in com-P = .07
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Figure 2. Change in log10 plasma RNA baseline levels for the time of study period. Arrows indicate time points of sampling. Dotted lines
represent patients from group 1 (baseline RNA levels !50 copies/mL, ); solid lines patients from group 2 (baseline RNA levels 50–400n = 11
copies/mL, ); and dashed lines patients from group 3 (baseline RNA levels 1400 copies/mL, ). Asterisks represent time points whenn = 5 n = 3
antiretroviral therapy was changed in individual patients.
Figure 3. Change in proviral DNA from baseline (copies/mg of genomic DNA). A, Mean proviral DNA changes from baseline in 8 patients
from group 1 (!50 human immunodeficiency virus [HIV] RNA copies/mL of plasma at baseline) with no detectable RNA during the entire study.
B, Mean proviral DNA changes in patients with !400 RNA copies/mL at baseline but in whom an RNA increase after vaccination was seen
( ). C, Mean of proviral DNA change in patients with 1400 plasma HIV RNA copies/mL at baseline ( ). Error bars represent the standardn = 8 n = 3
error of the mean. Baseline DNA levels for panels A–C are given on top of each graph. It should be noticed that the y-axis scale of panel C is
4-fold larger than that in panels A and B.
parison with the patient group that maintained undetectable
RNA levels over the study period (figure 3A, ).P = .13
Hemagglutination inhibition antibody response. Titers to all
3 influenza virus antigens increased after vaccination in all
groups (table 2). Hemagglutination inhibition antibody (HAI)
response of healthy controls was not stronger than that of the
HIV-infected patients. The immune response against A/NAN-
CHANG/933/95 (H3N2) was stronger in subjects with unde-
tectable plasma viremia (!50 copies/mL) at baseline, compared
with patients with detectable plasma HIV RNA ( ; tableP = .06
2). The response to A/JOHANNESBURG 82/97 (H1N1) was
weak in all the groups; only 2 of the 19 HIV-infected patients
and none of the healthy controls had a >4-fold increase in
antibody titer. Approximately one-third of HIV-infected sub-
jects showed a >4-fold increase against B/HARBIN/7/94 that
was distributed evenly among suppressed and unsuppressed
patients. At week 1 after vaccination, 6 of 11 patients who
developed a >4-fold increase in HAI antibody titer against at
least 1 of the 3 antigens tested also showed an increase in plasma
viremia, whereas only 2 of 8 patients with a !4-fold increase
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Table 2. Hemagglutination antibody (HAI) titers in human immundeficiency virus
(HIV)–infected patients at baseline and 4 weeks postvaccination, fold increase in
antibody titers, and proportion of individuals with a 4-fold increase in antibody titer
after influenza vaccination titer.
Vaccine, titer measurement
Patients grouped according to their
baseline plasma RNA levels
HIV-uninfected
control subjects
(n = 5)
!50 RNA c/mL
(n = 11)
150 c/mL
(n = 10)
A/Nanchang/933/95 (H3N2)
Baseline 18 (1–160) 25 (1–320) 2.4 (1–80)
Postvaccination 75 (20–320) 44 (20–160) 26 (20–80)
Fold increasea 21.6 5.7 16.2
% of patients >4-fold increaseb 47c (n = 5) 13c (n = 1) 0
A/Johannesburg/82/97 (H1N1)
Baseline 91 (20–320) 75 (20–320) 21 (1–320)
Postvaccination 141 (80–640) 92 (40–320) 24 (1–320)
Fold increasea 1.7 1.3 1.2
% of patients >4-fold increaseb 9 12 0
B/Harbin/7/94
Baseline 11 (1–320) 36 (1–640) 2.1 (1–40)
Postvaccination 66 (20–320) 106 (20–640) 12 (1–160)
Fold increasea 39 35 36.8
% of patients >4-fold increaseb 36 (n = 4) 30 (n = 3) 20 (n = 1)
NOTE. Data are mean (range) unless otherwise indicated.
a Mean of ratios between individual post/prevaccination titers. If subject’s baseline titer was
noninhibiting (!1 : 20) and increased to 1 : 20 after vaccination, the ratio would be 20.
b Percentage of patients who had at least a 4-fold increase of HAI titer when baseline titer
was clearly defined. If a baseline titer of !1 : 20 increased to 1 : 20 after vaccination, such an
increase would not be counted as 4-fold because exact baseline titer was not known
c , x2 test; hemagglutination inhibition titers are expressed as geometric means.P = .06
in antibody titer showed an increase in viral RNA ( ).P = .06
The mean HIV RNA increase in the 11 patients who had a
significant increase in antibody titer was 0.3 log10, compared
with only 0.003 log10 viral increase in the group of 8 patients
who lacked an increase in HAI titer ( ).P = .07
Lymphocyte subsets. In HIV-uninfected subjects ( ),n = 5
the mean increase in absolute CD41 cell count peaked 2 weeks
after vaccination and returned to baseline values by week 8
(figure 4A). A similar pattern was found for changes in per-
centage CD41 cells (figure 4B). The CD4 naive phenotype cells
(CD45RA1CD62L1) dropped transiently at weeks 1 and 2 and
returned to near baseline by weeks 4–8 (figure 4C). In parallel,
the mean percentage of activated CD4 memory cells
(CD45RO1CD251) increased at weeks 1–2 and returned to near
baseline by week 8 (figure 4D).
Changes in peripheral CD41 lymphocyte subsets from base-
line in the 19 HIV-infected patients were significantly distinct
( ) from those in healthy controls at weeks 1, 2, and 4P ! .05
(figure 4A–H, see asterisks). Total CD41 cell percentage and
absolute count did not change over time in the HIV-infected
patients, nor did the CD45RA162L1 naive cell subset of CD41
cells. However, in contrast to the increase in percentage of ac-
tivated CD4 memory cells (CD45RO1CD251) seen in the
healthy controls at weeks 1–2, a significant decrease in this
CD41 cell subset occurred in the HIV-infected subjects at weeks
2 and 4 (figure 4H). When peripheral CD41 lymphocyte subset
response patterns were stratified according to baseline plasma
HIV RNA levels, patients with !50 RNA copies at baseline
(group 1, ) showed a response more like that observedn = 11
in the HIV-uninfected controls (figure 5A, B, D, and E and
figure 6A, B), rather than that seen in patients with detectable
plasma viremia at baseline (group 2 and 3, , figure 5C, Fn = 8
and figure 6C). Patients from group 1 showed a significant
( ) decrease of activated CD4 memory cells at weeks 2P ! .05
and 4 (figure 6E) compared to healthy controls, in which an
increase was seen at weeks 1 and 2 (figure 6D). Patients in
group 2 showed a similar decrease, and patients from group 3
had no change. Figure 6F summarizes the mean changes of
group 2 and group 3 patients. The observed changes in lym-
phocyte subsets between patient groups 1, 2, and 3 were not
statistically significant.
Discussion
Previous studies have established that influenza vaccination
can increase HIV replication in patients with uncontrolled or
partially controlled viral replication [6–10]. However, there are
also various published reports in which plasma viremia did not
increase after vaccination [16–21]. A detailed analysis of all of
these studies by Fuller and colleagues has revealed that such a
discrepancy is probably the result of less-frequent sampling and
that transient plasma HIV RNA increases, which have been
reported to occur mostly during the first or second week after
vaccination, were simply missed [21]. We found that the fre-
quency and magnitude of viral RNA response to influenza vac-
cination was dependent on plasma RNA levels at baseline and,
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Figure 4. Mean changes from baseline in CD41 lymphocyte subsets. Error bars represent standard error of the mean. Change in healthy
controls ( ): (A) absolute CD4 count (cells/mm3); (B) % CD4 count; (C) % CD45 RA162L1 naive CD4 cells; (D) % CD45RO1CD251 memoryn = 5
CD4 cells. Change in all human immunodeficiency virus–infected patients ( ): (E) absolute CD4 count (cells/mm3); (F) % CD4 count; (G)n = 19
% CD45 RA162L1 naive CD4 cells; (H) % CD45RO1CD251 memory CD4 cells. Asterisks represent time points when mean changes significantly
differed between healthy controls and HIV-infected patients ( ).P ! .05
furthermore, was positively correlated with the ability to induce
a humoral immune response (>4-fold increase in HAI antibody
titers, ). In theory, potent antiretroviral therapy shouldP = .06
protect cells from a new infection; however, it will not stop
RNA transcription or production of virions from cells infected
before initiation of therapy. Therefore, increases in HIV plasma
RNA after vaccination, seen in subjects with undetectable vi-
remia at baseline, would be caused by either the upregulation
of viral production from low levels of transcription in chron-
ically infected cells or by the activation of latent HIV-1 from
resting CD4 memory cells.
The greatest increase of plasma HIV RNA after vaccination
was detected in patients from group 3 who had poorly con-
trolled, or uncontrolled, viremia at baseline (figures 1 and 2).
In addition, these subjects showed an increase in mean levels
of proviral DNA up to 4 weeks after vaccination (figure 3C).
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Figure 5. Comparison of absolute and percentage CD41 cell response patterns between healthy controls, patients with undetectable plasma
RNA levels at baseline (group 1, ), and patients with 150 RNA copies/mL at baseline (groups 2 and 3, ). CD41 absolute cell countsn = 11 n = 8
in: (A) healthy controls; (B) group 1 patients; and (C) group 2 and group 3 patients. % CD4 cells in: (D) healthy controls; (E) group 1 patients;
and (F) group 2 and group 3 patients.
Such findings are consistent with an increase in activated lym-
phocytes after influenza vaccination and subsequent infection
of these new target cells. The other end of the spectrum is
represented by the 8 subjects from group 1 who had no de-
tectable plasma HIV RNA and no change in proviral DNA
during the study period. In these subjects, the level of viral
replication and the number of chronically infected cells before
vaccination were very low or nonexistent, rendering detectable
upregulation of RNA expression unlikely. In these subjects,
potent antiretroviral therapy presumably blocked new infec-
tions by virus produced from activated, latently infected lym-
phocytes. Of note are the 3 patients from group 1 with a tran-
sient RNA increase and the 5 patients from group 2 who were
relatively suppressed at baseline but showed RNA increases
after vaccination in 4 of 5 subjects. In these combined 8 subjects,
a decrease of proviral DNA at weeks 2 and 4 was detected
(figure 3B) and was accompanied by a decrease in CD45RO1
CD4 memory cells.
Such observed drops in proviral DNA and numbers of ac-
tivated CD4 memory cells, in association with induction of
increased plasma viremia after vaccination, might have several
explanations. First, latently infected, resting CD4 memory cells
(CD45RO1) could have been lost after activation by influenza
vaccination, resulting in reduced levels of PBMC-associated
proviral DNA. In patients with low levels of ongoing viral
replication (!400 copies/mL at baseline), plasma RNA increases
probably resulted from upregulation of viral production from
chronically infected cells or from activation of latently infected
cells. Antiretroviral therapy was then largely successful in pre-
venting new infections of CD41 cells; and the destruction rate
of chronically infected and activated latent cells by the immune
system exceeded the rate of new infection. In agreement with
such an interpretation is a recent report by Chun et al., de-
scribing a reduced frequency of latently infected, quiescent
CD4RO1 memory cells in patients enrolled in a cross-sectional
study treated with IL-2 and potent antiretroviral therapy when
compared with patients treated with potent antiretroviral ther-
apy alone [22]. However, it has to be kept in mind that the 2
studies differed in design and methods and therefore are only
partially comparable
Alternatively, observed drops in cell-associated viral DNA
might represent a dilutional phenomenon in which the fre-
quency of PBMC-harboring HIV was reduced because of the
expansion of uninfected T cell subsets or the preferential re-
distribution of HIV-infected cells. The fact that HIV proviral
DNA, as well as CD41 memory cells, returned to baseline levels
by week 8 could also be explained by ongoing low-level viral
replication [23–24] within a different compartment outside the
peripheral circulation and later redistribution events or by sim-
ple redistribution of transiently sequestered, latently infected
CD4 memory cells.
In uninfected control subjects a distinct response pattern of
T cell phenotype changes was observed after influenza vacci-
nation (figure 4A–D). It consisted of a transient increase in the
absolute number and percentage CD41 lymphocytes and in the
proportion of activated memory CD4 cells (CD45RO1
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Figure 6. Comparison of % CD45RA162L1 CD4 naive and % CD45RO1CD251 CD4 memory phenotype response patterns between healthy
controls, patients with undetectable plasma RNA levels at baseline (group 1, ), and patients with 150 RNA copies/mL at baseline (groupsn = 11
2 and 3, ). % CD45RA162L1 CD4 naive cells in: (A) healthy controls; (B) group 1; and (C) groups 2 and 3. % CD45RO1CD251 CD4n = 8
memory cells in: (D) healthy controls; (E) group 1; and (F) groups 2 and 3.
CD251), along with a transient decrease in the proportion of
naive CD41 cells (CD45RA162L1).
The response pattern seen in HIV-infected patients differed
considerably (figure 4E–H) and seemed to be dependent on the
level of suppression of viral replication at baseline. In patients
with the most complete suppression of viral replication (group
1), changes in absolute CD41 cell numbers and in proportions
of CD4-naive cells resembled those seen in the HIV-uninfected
subjects (figure 5A, B, D, E and figure 6A, B), whereas the T
cell subset patterns of patients with 150 RNA copies/mL at
baseline looked distinct (figure 5C, F and figure 6C). Of par-
ticular interest was the observation that the proportion of mem-
ory CD4 cells transiently declined in all HIV-infected patients,
contrary to the increases seen in the HIV-uninfected controls.
In subjects with chronic HIV infection, CD4 memory cell loss
and dysfunction is common; therefore, specific influenza recall
antigen activation and clonal expansion are less likely to occur.
In addition, if such antigen-specific memory cells harbored la-
tent HIV infection, they might be lost on activation and virus
production because of direct cytopathology by HIV or lysis by
cytotoxic effector T cells. Such a mechanism would also explain
the parallel decrease observed in HIV proviral DNA. In con-
trast, redistribution of lymphocyte subsets could also account
for these observations. In HIV-infected patients, memory CD4
cells trafficking to regional lymph nodes could become infected
with HIV during response to influenza antigen stimulation and
die within the tissue microenvironment without exiting into the
peripheral circulation, or responding CD41 cells could become
“trapped” for extended time periods because of inappropriate
expression of adhesion molecules in HIV-infected nodes.
It has been shown that humoral immune responses in HIV-
infected patients are weaker than those in healthy controls [7,
25] and are proportional to the levels of CD41 cells in peripheral
blood. The patients in our study showed an HAI response to
influenza virus antigens in the range of those previously re-
ported by others [7, 16, 17, 21, 25]. However, we found that
patients with undetectable plasma viremia at baseline showed
a stronger humoral immune response ( ) against 1 HAP = .06
antigen [A/Nanchang/933/95 (H3N2)] than did patients who
where not virologically suppressed (table 2). The better anti-
body response of patients without viremia was independent of
their CD4 cell count. A recently published study found similar
results [21]. This finding, together with our observation that
the response pattern of peripheral lymphocyte subsets of pa-
tients with undetectable baseline RNA levels resembled those
of uninfected subjects, suggests that control of viral replication
alone can significantly improve humoral, and maybe cellular,
immune function in HIV-infected patients before any significant
increases in peripheral CD41 cell numbers. In our HIV-unin-
fected control group, HAI antibody response was poor, even
though prevaccination influenza antibody status was compa-
rable (80% of HIV-infected and healthy controls) and the same
vaccine was used.
The transient increases in plasma RNA, after vaccination,
returned to baseline in group 1, but not in group 2 and group
3, subjects. Whether persistence of increased viremia in some
530 Gu¨nthard et al. JID 2000;181 (February)
patients was the direct result of influenza vaccination or because
of chance therapeutic failure cannot be answered, because ther-
apy is less likely to succeed in patients with ongoing low-level
plasma viremia (50–400 copies/mL) [26–28]. However, a pre-
vious study of patients receiving influenza vaccination showed
a significant increase in HIV plasma RNA 1 month after vac-
cination and decreased CD41 cell counts after 3 months, com-
pared with nonvaccinated, HIV-infected subjects [10]. Small
sample size and the short duration of follow up in our cohort
does not permit us to address the question of benefit versus
risk of influenza vaccine in different patient groups.
In summary, our study showed that influenza vaccination
increased plasma HIV RNA levels in patients on potent anti-
retroviral therapy who had !400 RNA copies/mL at baseline.
The frequency and magnitude of HIV RNA induction was
dependent on baseline viral load and was more likely to occur
in patients who were capable of mounting a humoral immune
response to vaccination. In conjunction, the humoral immune
response to influenza vaccination was substantially improved
by suppression of viremia, independent of CD41 cell levels.
Furthermore, the transient drop of PBMC-associated proviral
DNA with a parallel decrease in CD45RO1 CD4 memory cells,
in patients with a low baseline viral load (!400 copies/mL) and
an RNA increase upon vaccination, suggested that this phe-
nomenon either represented the activation and killing of la-
tently infected, quiescent CD4 memory cells, the killing of
chronically infected cells, or the redistribution of CD41 cells
harboring proviral DNA. In formulating better therapeutic
strategies, establishing the potential for activation and mobi-
lization of the latent reservoir is of major conceptual impor-
tance. The results of this study support the feasibility of such
an approach.
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